Product details
Background：CD117 (also known as c-KIT or SCF receptor) is a gene that encodes the Stem Cell Factor Receptor (SCFR) and belongs to the type I tyrosine kinase receptor family. Briquilimab works by binding to CD117, blocking the function of the Stem Cell Factor receptor and thereby affecting the behavior of cells dependent on the CD117 signaling pathway. As an innovative monoclonal antibody targeting CD117, Briquilimab has shown significant potential in hematopoietic stem cell transplantation, immune regulation, and the treatment of related diseases, making it a promising low-toxicity and highly effective novel therapy.
